NEUROMETRIX INC (NURO)

NeuroMetrix Announces Steps Taken to Enhance Shareholder Value

NeuroMetrix today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders....

Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)

NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that...

NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia

NeuroMetrix today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in Dec...

NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights

NeuroMetrix, Inc. today reported financial and business highlights for the quarter and full year ended December 31, 2023. ...

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call

NeuroMetrix plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the market on February 22, 2024. ...

NeuroMetrix announces review of strategic options for business growth (NASDAQ:NURO)

NeuroMetrix, Inc. reveals plans to review strategic options and maximize shareholder value through potential acquisitions, sales, and other transactions.

NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value

WOBURN, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), a commercial stage medical device company focused on reducing the...

NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024

NeuroMetrix announced today that the Company’s Chairman and CEO, Dr. Shai N. Gozani will present at the Emerging Growth Conference on January 10, 2024....

NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)

NeuroMetrix reported the recent presentation of data from a clinical trial of Quell wearable neuromodulation technology in patients with Long COVID....

NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)

NeuroMetrix noted publication of results from a NIH-funded clinical trial of Quell. The paper has been electronically published in The Journal of Pain....

NeuroMetrix Announces One-for-Eight Reverse Stock Split

WOBURN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that it will effect a one-for-eight reverse split of...

NeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023

NeuroMetrix, Inc. announced today that it will present at the Emerging Growth Conference on Wednesday November 1, 2023 at 3:40PM EDT....

NeuroMetrix Reports Q3 2023 Business Highlights

NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and nine month period ended September 30, 2023. ...

NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference Call

NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia

NeuroMetrix, Inc. announced that it has been selected as a Proud Sponsor of the National Fibromyalgia Association (NFA)....

NeuroMetrix to Present at the Emerging Growth Conference on October 4, 2023

NeuroMetrix, Inc. announced today that it will present at the Emerging Growth Conference on October 4, 2023 at 3:55pm EDT....

NeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023

WOBURN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference...

NeuroMetrix Reports Q2 2023 Business Highlights

WOBURN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and...

NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call

WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q2 2023 business and...

NeuroMetrix Announces Sales Force Expansion for Quell Fibromyalgia

WOBURN, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced expansion of its sales force to drive further adoption...

Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients

WOBURN, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of two large studies that support the...

Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical Study

WOBURN, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted presentation of new clinical data at the Diabetes UK meeting held...

Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)

WOBURN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted publication of an abstract describing partial results from a...

NeuroMetrix Reports Q1 2023 Financial Results

WOBURN, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended...

NeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference Call

WOBURN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2023 first quarter...

NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting

WOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain...

NeuroMetrix Reports Q4 and Full Year 2022 Financial Results

WOBURN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and...

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call

WOBURN, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 fourth quarter and year...

NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

Point-of-care technology helps healthcare providers rapidly identify at-risk patients...

NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting

WOBURN, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will introduce Quell Fibromyalgia at the American College of...